<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347.2017.11.2.005-011</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-403</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ОRIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group></article-categories><title-group><article-title>USE OF INTEGRATED DIFFUSION-WEIGHTED MAGNETIC-RESONANCE IMAGING IN PRE-OPERATIVE EVALUATION OF RESECTABILITY OF ADVANCED OVARIAN CANCER</article-title><trans-title-group xml:lang="ru"><trans-title>ПРИМЕНЕНИЕ КОМПЛЕКСНОЙ МАГНИТНО-РЕЗОНАНСНОЙ ТОМОГРАФИИ С ДИФФУЗИОННОВЗВЕШЕННЫМИ ПОСЛЕДОВАТЕЛЬНОСТЯМИ В ПРЕДОПЕРАЦИОННОЙ ОЦЕНКЕ РЕЗЕКТАБЕЛЬНОСТИ РАСПРОСТРАНЕННОГО РАКА ЯИЧНИКОВ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4768-115X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Солопова</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Solopova</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Солопова Алина Евгеньевна - кандидат медицинских наук, доцент кафедры лучевой диагностики и лучевой терапии лечебного факультета </p><p>Адрес: ул. Трубецкая, 8, стр. 2, Москва, 119991.</p></bio><bio xml:lang="en"><p>Solopova Alina Evgenievna - PhD, Assistant Professor, Department of Radiation Diagnostics and Radiation Therapy, Faculty of Internal Diseases </p><p>Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991</p></bio><email xlink:type="simple">dr.solopova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4374-1063</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терновой</surname><given-names>С. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Ternovoy</surname><given-names>S. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Терновой Сергей Константинович - доктор медицинских наук, академик РАН, профессор, заведующий кафедрой лучевой диагностики и лучевой терапии лечебного факультета </p><p>Адрес: ул. Трубецкая, 8, стр. 2, Москва, 119991.</p></bio><bio xml:lang="en"><p>Ternovoy Sergey Konstantinovich - MD, Professor, academician of Russian Academy of Sciences, Head of Department of Radiation Diagnostics and Radiation Therapy, Faculty of Internal Diseases </p><p>Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991</p></bio><email xlink:type="simple">prof_ternovoy@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4430-5258</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алипов</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Alipov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алипов Владимир Иванович - студент лечебного факультета </p><p>Адрес: ул. Трубецкая, 8, стр. 2, Москва, 119991.</p></bio><bio xml:lang="en"><p>Alipov Vladimir Ivanovich - student, Faculty of Internal Diseases </p><p>Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991</p></bio><email xlink:type="simple">alipvladimir@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1395-567X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макацария</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Makatsariya</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Макацария Александр Давидович - доктор медицинских наук, член-корреспондент РАН, профессор, заведующий кафедрой акушерства и гинекологии медико-профилактического факультета </p><p>Адрес: ул. Трубецкая, 8, стр. 2, Москва, 119991.</p></bio><bio xml:lang="en"><p>Makatsariya Aleksandr Davidovich - MD, corresponding member of Russian Academy of Sciences, Professor, Head of Department of Obstetrics and Gynecology, Faculty of Preventive Medicine </p><p>Address: ul. Trubetskaya, 8, str. 2, Moscow, Russia, 119991</p></bio><email xlink:type="simple">gemostasis@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>22</day><month>08</month><year>2017</year></pub-date><volume>11</volume><issue>2</issue><fpage>5</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Solopova A.E., Ternovoy S.K., Alipov V.I., Makatsariya A.D., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Солопова А.Е., Терновой С.К., Алипов В.И., Макацария А.Д.</copyright-holder><copyright-holder xml:lang="en">Solopova A.E., Ternovoy S.K., Alipov V.I., Makatsariya A.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/403">https://www.gynecology.su/jour/article/view/403</self-uri><abstract><p>The aim of the study was to compare the diagnostic potential of integrated diffusion-weighted magnetic-resonance imaging (DW-MRI) with multi-spiral computed tomography (MSCT) in pre-operative evaluation of resectability of advanced ovarian cancer. Materials and methods. In the period from February to December 2016, 73 patients with suspected malignant neoplasms of the ovaries underwent preoperative examination, including abdominal/pelvic integrated DW-MRI or MSCT. The DW-MRI test was run using a 1,5 T scanner (b-factors of 0-1000 s/mm2) able to compute the apparent diffusion coefficient (ADC). For each of the two methods, we calculated the peritoneal cancer indices (PCI) and the informational values pertaining to the critical areas of the peritoneal cavity and the pelvis, and compared them with the surgical findings. We used the following criteria to conclude that a surgical intervention would not achieve the optimal cytoreduction: lesions of the omental bursa (&gt; 1 cm); foci in the diaphragm area (&gt; 2 cm); foci on the liver surface (&gt; 2 cm); mesentery lesions of the small and/or large intestine (&gt;1 cm); involvement of para-aortic lymph nodes; metastases to the parenchymal organs (liver, spleen) and the PCI &gt; 20. Results. The sensitivity of DW-MRI vs MSCT was 78,3% vs 50%; and the specificity of DW-MRI vs MSCT was 78% vs 87%, respectively. The DW-MRI based prediction on the impossibility of effective surgical cytoreduction was correct in 92% of patients. The similar figure for MSCT was 64% of patients with inoperable tumors. Conclusion. DW-MRI is an accurate instrument for pre-operative assessment of the involvement of the peritoneum and abdominal organs in the tumor process. Based on this method, it is possible to develop a sensitive and specific algorithm for evaluating the resectability of ovarian cancer, thus avoiding unnecessary surgical intervention.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования: сравнить возможности комплексного магнитно-резонансного исследования с использованием диффузионно-взвешенных последовательностей (ДВ-МРТ) и мультиспиральной компьютерной томографии (МСКТ) в предоперационной оценке резектабельности распространенного рака яичников. Материалы и методы. В период с февраля 2016 года по декабрь 2016 года 73 пациенткам с подозрением на злокачественные новообразования яичников было выполнено МСКТ и комплексное ДВ-МРТ исследование брюшной полости и малого таза в рамках предоперационного обследования. ДВ-МРТ выполнялось на 1,5 Тл томографе с b-факторами 0 и 1000 с/мм2 с построением карт измеряемого коэффициента диффузии. Для каждого из методов был определен индекс перитонеального канцероматоза (ИПК) и показатели информативности для значимых областей брюшной полости и малого таза в сравнении с данными, полученными во время операции. В качестве критериев невозможности проведения оптимальной циторедукции были выбраны: поражение сальниковой сумки (&gt; 1 см); наличие очагов в области диафрагмы (&gt; 2 см); наличие очагов на поверхности печени (&gt; 2 см); поражение брыжейки тонкого и/или толстого кишечника (&gt; 1 см); поражение парааортальных лимфоузлов; метастазы в паренхиматозные органы (печень, селезенку) и ИПК&gt; 20. Результаты. Чувствительность и специфичность для ДВ-МРТ и МСКТ составили 78,3% и 78%; 50% и 87%, соответственно. С помощью ДВ-МРТ в 92% случаев удалось правильно определить невозможность проведения оптимальной циторедукции, с помощью МСКТ удалось правильно оценить лишь 64% пациенток с неоперабельными опухолями. Заключение. ДВ-МРТ представляет собой точный инструмент предоперационной оценки вовлеченности брюшины и органов брюшной полости в опухолевый процесс. На основе этого метода можно составить алгоритм оценки резектабельности рака яичников с высокой чувствительностью и специфичностью, что позволит избежать излишнего хирургического вмешательства.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>магнитно-резонансная томография</kwd><kwd>диффузионно-взвешенные последовательности</kwd><kwd>оптимальная циторедукция</kwd><kwd>рак яичников</kwd></kwd-group><kwd-group xml:lang="en"><kwd>magnetic-resonance imaging</kwd><kwd>diffusion-weighted sequences</kwd><kwd>optimal cytoreduction</kwd><kwd>ovarian cancer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Siegel R.L., Miller K.D., Jemal A. Cancer statistics. 2015. CA Cancer J Clin. 2015; 65 (1): 5-29.</mixed-citation><mixed-citation xml:lang="en">Siegel R.L., Miller K.D., Jemal A. Cancer statistics. 2015. CA Cancer J Clin. 2015; 65 (1): 5-29.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet. 2014; 384 (9951): 1376-88.</mixed-citation><mixed-citation xml:lang="en">Jayson G.C., Kohn E.C., Kitchener H.C., Ledermann J.A. Ovarian cancer. Lancet. 2014; 384 (9951): 1376-88.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kandukuri S.R., Rao J. FIGO 2013 staging system for ovarian cancer: what is new in comparison to the 1988 staging system. Curr Opin Obstet Gynecol. 2015; 27: 48-52.</mixed-citation><mixed-citation xml:lang="en">Kandukuri S.R., Rao J. FIGO 2013 staging system for ovarian cancer: what is new in comparison to the 1988 staging system. Curr Opin Obstet Gynecol. 2015; 27: 48-52.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol. 2013; 24 (Suppl 6): vi24-32.</mixed-citation><mixed-citation xml:lang="en">Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up. Ann Oncol. 2013; 24 (Suppl 6): vi24-32.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363 (10): 943-53.</mixed-citation><mixed-citation xml:lang="en">Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363 (10): 943-53.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Winter W.E., Maxwell G.L, Tian C., Sundborg M.J., Rose G.S., Rose P.G., Rubin S.C., Muggia F., McGuire W.P. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008; 26: 83-9.</mixed-citation><mixed-citation xml:lang="en">Winter W.E., Maxwell G.L, Tian C., Sundborg M.J., Rose G.S., Rose P.G., Rubin S.C., Muggia F., McGuire W.P. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008; 26: 83-9.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu Rustum N.R., Sonoda Y., Levine D.A., Hensley M., Barakat R.R. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006; 103 (2): 559-64.</mixed-citation><mixed-citation xml:lang="en">Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu Rustum N.R., Sonoda Y., Levine D.A., Hensley M., Barakat R.R. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol. 2006; 103 (2): 559-64.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Hoppenau B., du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO- OVAR). Gynecol Oncol. 2007; 106 (1): 69-74.</mixed-citation><mixed-citation xml:lang="en">Wimberger P., Lehmann N., Kimmig R., Burges A., Meier W., Hoppenau B., du Bois A. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO- OVAR). Gynecol Oncol. 2007; 106 (1): 69-74.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Winter W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., Markman M., Armstrong D.K., Muggia F., McGuire W.P. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25 (24): 3621-7.</mixed-citation><mixed-citation xml:lang="en">Winter W.E., Maxwell G.L., Tian C., Carlson J.W., Ozols R.F., Rose P.G., Markman M., Armstrong D.K., Muggia F., McGuire W.P. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007; 25 (24): 3621-7.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rauh^ain J.A., Rodriguez N., Growdon W.B., Goodman A.K., Boruta D.M., Horowitz N.S., Del Carmen M.G., Schorge J.O. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012; 19 (3): 959-65.</mixed-citation><mixed-citation xml:lang="en">Rauh^ain J.A., Rodriguez N., Growdon W.B., Goodman A.K., Boruta D.M., Horowitz N.S., Del Carmen M.G., Schorge J.O. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012; 19 (3): 959-65.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Van Мeurs H.S., Tajik P., Hof M.H., Vergote I., Kenter G.G., Mol B.W., Buist M.R., Bossuyt P.M. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organization for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013; 49 (15): 3191-201.</mixed-citation><mixed-citation xml:lang="en">Van Мeurs H.S., Tajik P., Hof M.H., Vergote I., Kenter G.G., Mol B.W., Buist M.R., Bossuyt P.M. Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organization for Research and Treatment of Cancer 55971 randomised trial. Eur J Cancer. 2013; 49 (15): 3191-201.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Forstner R., Sala E., Kinkel K., Spencer J.A. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010; 20 (12): 2773-80.</mixed-citation><mixed-citation xml:lang="en">Forstner R., Sala E., Kinkel K., Spencer J.A. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010; 20 (12): 2773-80.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Rockall A.G. Diffusion weighted MRI in ovarian cancer. Curr Opin Oncol. 2014; 26 (5): 529-35.</mixed-citation><mixed-citation xml:lang="en">Rockall A.G. Diffusion weighted MRI in ovarian cancer. Curr Opin Oncol. 2014; 26 (5): 529-35.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Suidan R.S., Ramirez P.T., Sarasohn D.M., Teitcher J.B., Mironov S., Iyer R.B. et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014; 134 (3): 455-61.</mixed-citation><mixed-citation xml:lang="en">Suidan R.S., Ramirez P.T., Sarasohn D.M., Teitcher J.B., Mironov S., Iyer R.B. et al. A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. Gynecol Oncol. 2014; 134 (3): 455-61.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sugarbaker P.H. Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. Michigan: Ludann Company, 1998.</mixed-citation><mixed-citation xml:lang="en">Sugarbaker P.H. Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. Michigan: Ludann Company, 1998.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mizumoto A., Canbay E., Hirano M., Takao N., Matsuda T., Ichinose M., Yonemura Y. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. 2012; 2012: 836425.</mixed-citation><mixed-citation xml:lang="en">Mizumoto A., Canbay E., Hirano M., Takao N., Matsuda T., Ichinose M., Yonemura Y. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. 2012; 2012: 836425.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Casado^dam A., Alderman R., Stuart O.A., Chang D., Sugarbaker P.H. Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol. 2011; 2011: 468698.</mixed-citation><mixed-citation xml:lang="en">Casado^dam A., Alderman R., Stuart O.A., Chang D., Sugarbaker P.H. Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol. 2011; 2011: 468698.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Heintz A.P., Hacker N.F., Berek J.S., Rose T., Munoz A., Lagasse L. Cytoreductive surgery in ovarian carcinoma: feasibility and mortality. Obstet Gynecol. 1986; 67 (Suppl 6): 783-8.</mixed-citation><mixed-citation xml:lang="en">Heintz A.P., Hacker N.F., Berek J.S., Rose T., Munoz A., Lagasse L. Cytoreductive surgery in ovarian carcinoma: feasibility and mortality. Obstet Gynecol. 1986; 67 (Suppl 6): 783-8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Farias-Eisner R., Teng F., Oliveira M., Leuchter R., Karlan B., Lagasse L.D. et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol. 1994; 55 (1): 108-10.</mixed-citation><mixed-citation xml:lang="en">Farias-Eisner R., Teng F., Oliveira M., Leuchter R., Karlan B., Lagasse L.D. et al. The influence of tumor grade, distribution, and extent of carcinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol. 1994; 55 (1): 108-10.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nelson B.E., Rosenfield A.T., Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 1993; 11 (1): 166-72.</mixed-citation><mixed-citation xml:lang="en">Nelson B.E., Rosenfield A.T., Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol. 1993; 11 (1): 166-72.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007; 25 (4): 384-9.</mixed-citation><mixed-citation xml:lang="en">Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol. 2007; 25 (4): 384-9.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Low R.N., Barone R.M. Combined diffusion- weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012; 19 (5): 1394-1401.</mixed-citation><mixed-citation xml:lang="en">Low R.N., Barone R.M. Combined diffusion- weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012; 19 (5): 1394-1401.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Low R.N., Barone R.M., Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015; 22 (5): 1708-15.</mixed-citation><mixed-citation xml:lang="en">Low R.N., Barone R.M., Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015; 22 (5): 1708-15.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Michielsen K., Vergote I., Op de 8eeck K., Amant F., Leunen K., Moerman P. et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014; 24 (4): 889-901.</mixed-citation><mixed-citation xml:lang="en">Michielsen K., Vergote I., Op de 8eeck K., Amant F., Leunen K., Moerman P. et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol. 2014; 24 (4): 889-901.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Espada M., Garcia-flores J.R., Jimenez M., Alvarez-Moreno E. Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma. Eur Radiol. 2013; 23 (9): 2636-42.</mixed-citation><mixed-citation xml:lang="en">Espada M., Garcia-flores J.R., Jimenez M., Alvarez-Moreno E. Diffusion-weighted magnetic resonance imaging evaluation of intra-abdominal sites of implants to predict likelihood of suboptimal cytoreductive surgery in patients with ovarian carcinoma. Eur Radiol. 2013; 23 (9): 2636-42.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
